Author:
Schulman Ariel,Eshghi Majid
Publisher
Springer International Publishing
Reference23 articles.
1. Transitional cell cancer of the renal pelvis and ureter treatment—for health professionals (PDQ) Bethesda (MD): National Cancer Institute; 2015. Available at: http://www.cancer.gov/types/kidney/hp/transitional-cell-treatment-pdq . Accessed 12 Oct 2015.
2. Kates M, Badalato GM, Gupta M, McKiernan JM. Secondary bladder cancer after upper tract urothelial carcinoma in the US population. BJU Int. 2012;110(9):1325–9.
3. Lucca I, Leow JJ, Shariat SF, Chang SL. Diagnosis and management of upper tract urothelial carcinoma. Hematol Oncol Clin North Am. 2015;29(2):271–88.
4. Raman JD, Messer J, Sielatycki JA, Hollenbeak CS. Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973–2005. BJU Int. 2011;107(7):1059–64.
5. Davis R, Jones JS, Barocas DA, Castle EP, Lang EK, Leveillee RJ, Messing EM, Miller SD, Peterson AC, Turk TMT, Weitzel W. Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. Linthicum (MD): American Urological Association; 2012. Available at: https://www.auanet.org/education/guidelines/asymptomatic-microhematuria.cfm . Accessed 15 Oct 2015.